Recipharm to open new GLP bioanalysis laboratory in Sweden
Recipharm, the contract development and manufacturing organisation (CDMO), has announced a 5 million SEK investment into a new GLP (Good Laboratory Practice) compliant bioanalysis laboratory at its development facility in Uppsala, Sweden, in response to growing customer demand.
The investment will see the opening of a 500 square metre purpose-built facility in November 2016, which will become the largest GLP bioanalysis laboratory of its kind in the Nordic countries.
Recipharm’s development team in Uppsala specialises in medicinal chemistry, offering synthesis and analytical preclinical development services to drug development companies progressing products through clinical trials.
From its new laboratory, the CDMO will significantly increase its capacity, with the capability to process more than 10,000 plasma samples per week.
Commenting on the investment, Fredrik Lehmann, General Manager at Recipharm Development in Uppsala said: “This is a strategic investment for Recipharm as there is a real need for more GLP bioanalysis laboratories in the Nordic region.
Bioanalysis requires specialist expertise and establishing the necessary capabilities can be a costly investment, proving a barrier to entry for many contract services providers. Having first started out in a collaboration with a subcontractor, we are now delighted to be able to expand our offering in-house to service an unmet need for bioanalysis capabilities”.
“The new laboratory will dramatically increase our capacity, allowing us to continue to grow our European customer base and expand our expert team of chemists,” added Fredrik.
In order to support the increasing demand of bioanalysis services, Recipharm Development in Uppsala plans to recruit several new PhD level chemists in the coming months and aims to more than double its team of 35 in the next couple of years.
Contact information
Fredrik Lehmann, General Manager, fredrik.lehmann@recipharm.com, +46 73 354 12 39
Carl-Johan Spak, Executive Vice President Global Technologies, carl-johan.spak@recipharm.com,
+46 8 602 53 13
For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com, +44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and its services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03
www.recipharm.com
Tags: